ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
BioSpring, a contract manufacturer of oligonucleotides for the drug industry, says it plans a major expansion in Offenbach, Germany, that could create as many as 1,500 jobs. The firm, which today has close to 500 employees, is purchasing 30,000 m2 of land in the city’s Innovation Campus, where it plans to boost its production capacity by up to 30 times over the long term. Oligos are short strands of DNA or RNA that are growing in use as active ingredients for antisense and genome-editing therapies.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X